OxSHIELD:
Electron Supplementation Empowerment.
Anywhere. Anytime. On Earth. In Orbit.
The Opportunity
Oxidative stress from reactive oxygen species (ROS) contributes to aging, disease, and spaceflight health issues. No current wearable effectively addresses electron depletion—a core ROS driver
The OxSHIELD Solution
A patent-pending wearable textile device that delivers electrons to reduce ROS and support whole-body health. Dual-use: astronauts and everyday consumers.
Traction & Validation
NASA’s TRISH has expressed interest in testing for OxSHIELD in 2026
Nicole Stott, NASA Astronaut (Ret.):
“OxSHIELD’s potential for astronaut health is exciting.”
Both Dr. Dorit Donoviel and Nicole Stott have expressed personal interest in using OxSHIELD
Provisional patent filed, utility patent submission planned (2026)
Business Model & Revenue Potential
OxSHIELD’s revenue model reflects a breakout opportunity in the global wellness and performance recovery market. With over-the-counter (OTC) sales forecast to exceed $100 million annually by 2031, OxSHIELD capitalizes on the consumer demand for natural, wearable recovery solutions. The device’s early go-to-market strategy targets direct-to-consumer e-commerce and retail distribution, while parallel efforts drive FDA medical device clearance and CPT reimbursement for clinical use. Simultaneously, OxSHIELD’s alignment with NASA and Department of Defense initiatives opens a powerful strategic lane through military and aerospace contracts. Combined, this four-stream revenue approach positions OxSHIELD to generate over $175 million annually by 2032, offering investors both rapid market access and long-term scale with defensible IP and real-world impact.
| Year | OTC Wellness Sales | FDA Device Sales | CPT Reimbursement | Military & Space Contracts | Total Revenue Estimate |
|---|
| Year | OTC Wellness Sales | FDA Device Sales | CPT Reimbursement | Military & Space Contracts | Total Revenue Estimate |
|---|
| 2027 | $7M (35K units @ $199) | — | — | $0.5M (NASA/TRISH) | $7.5M |
| 2028 | $25M (125K units @ $199) | — | — | $1.5M (DoD/Air Force) | $26.5M |
| 2029 | $50M (250K units @ $199) | $10M (20K @ $499) | $3.6M (5K CPT patients) | $4M (military/aerospace) | $67.6M |
| 2030 | $75M (375K units @ $199) | $25M (50K @ $499) | $14.4M (20K CPT) | $7.5M (DoD/VA deployments) | $121.9M |
| 2031 | $100M (500K units @ $199) | $40M (80K @ $499) | $28.8M (40K CPT) | $10M+ (global military/space) | $178.8M+ |
Meet the Founder
John Hynds, Founder and CEO of Grounded Ventures, is a former U.S. Marine and Peterson Fellow with an MBA from the Acton School of Business. With over 45 years of high-tech leadership, including his role as CTO of ClearStream Communications and as a 2x patent holder, John brings deep expertise in innovation, engineering oversight, and startup execution. A 16-year CrossFit athlete with a passion for human performance and recovery, he brings that same discipline and mission-driven focus to OxSHIELD. “OxSHIELD is my mission to make recovery, vitality, and performance accessible—from astronauts in orbit to everyday people here on Earth.”
John Hynds
Founder & CEO
Advisors & Strategic Partners
Nicole Stott, NASA Astronaut (Ret.) – Publicly endorses OxSHIELD
SGW Design Works – Engineering and hardware development
Randall Danskin – Patent Counsel
TRISH / NASA – Endorsed testing partner
Why Investors Are Joining Early
NASA-backed testing and endorsements de-risk early adoption
$175M+ revenue potential with strong OTC and healthcare strategies
Defensible IP with patents and FDA strategy underway
Multi-market targeting across wellness, clinical, and government
Exit-ready channels: Licensing, acquisition by wellness or medtech firms
Investor Access & Contact
Interested in Investing?
Please complete the short form below for information requests and direct Q&A with our founder.
📩 Email: JohnHynds@proton.me
🌐 Website: grounded-ventures.com
Legal & Compliance Notice
This site and its contents are for informational purposes only and do not constitute an offer to sell or a solicitation of an offer to buy securities. Offers may only be made to accredited investors under appropriate legal exemptions. OxSHIELD is a trademark of Grounded Ventures LLC. All information is subject to change.
© 2025 Grounded Ventures LLC. All rights reserved.
OxSHIELD™ is patent-pending.
The OxSHIELD device is not intended to diagnose, treat, cure, or prevent any disease.